Company Announcement, Helsinki, 25 April 2023 at 3 PM (EEST)
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announced on April 18, 2023 that pursuant to the authorisation received from the Company's Annual General Meeting on March 31, 2023, and the restricted share unit reward plan approved by the Annual General Meeting on March 26, 2016, the Board of Directors of the Company had resolved on issuing altogether 9 540 new shares without payment to members of the Board of Directors.
These shares have been registered in the Trade Register on April 25, 2023, as of which date the new shares will establish shareholder rights. After the trade registration the total amount of shares for Nexstim Plc is 6,764,562.
The shares will be traded in the Nasdaq Helsinki Plc’s First North Growth Market Finland marketplace as an additional lot with the company’s old shares starting April 26, 2023.
The terms and conditions of stock option programs with additional information are available on the company's website at https://www.nexstim.com/investors/.
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
The Company’s Certified Advisor is Erik Penser Bank.
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com